Months af­ter shock­ing in­vestors with lung can­cer win, Be­yond­Spring's lead drug hits road­block at the FDA

Be­yond­Spring shocked in­vestors in ear­ly Au­gust af­ter its once-mar­gin­al lead drug sud­den­ly showed a lot of promise in a com­mon form of lung can­cer. With hopes high, the FDA has now slammed the door on that drug in an­oth­er in­di­ca­tion — does that spell bad news for Be­yond­Spring’s Cin­derel­la sto­ry?

The FDA is­sued Be­yond­Spring a com­plete re­sponse let­ter for its plinab­u­lin in com­bi­na­tion with gran­u­lo­cyte colony-stim­u­lat­ing fac­tor (G-CSF) for the pre­ven­tion of chemother­a­py-in­duced neu­trope­nia, ef­fec­tive­ly shut­ting down the drug’s im­me­di­ate chances at a mar­ket­ing ap­proval, the biotech said Wednes­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER